KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Gsk (GSK) EBITDA (2016 - 2026)

Gsk has reported EBITDA over the past 18 years, most recently at $3.1 billion for Q1 2026.

  • For Q1 2026, EBITDA rose 10.76% year-over-year to $3.1 billion; the TTM value through Mar 2026 reached $10.8 billion, up 17.65%, while the annual FY2025 figure was $10.6 billion, 104.44% up from the prior year.
  • EBITDA for Q1 2026 was $3.1 billion at Gsk, up from $1.5 billion in the prior quarter.
  • Over five years, EBITDA peaked at $5.2 billion in Q4 2023 and troughed at $245.6 million in Q3 2024.
  • A 5-year average of $2.6 billion and a median of $2.7 billion in 2023 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: tumbled 90.05% in 2024 and later surged 1324.82% in 2025.
  • Year by year, EBITDA stood at $4.0 billion in 2022, then skyrocketed by 32.44% to $5.2 billion in 2023, then decreased by 23.21% to $4.0 billion in 2024, then crashed by 63.65% to $1.5 billion in 2025, then skyrocketed by 111.28% to $3.1 billion in 2026.
  • Business Quant data shows EBITDA for GSK at $3.1 billion in Q1 2026, $1.5 billion in Q4 2025, and $3.5 billion in Q3 2025.